COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

被引：0
|
作者：
Lindgren, P. [1 ]
Hagstrom, E. [2 ]
van Hout, B. [3 ]
Villa, G. [4 ]
Pemberton-Ross, P. [4 ]
Arellano, J. [5 ]
Sibartie, M. [4 ]
Fonarow, G. C. [6 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Amgen Europe GmbH, Rotkreuz, Switzerland
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV40
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [31] Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
    O'Donoghue, Michelle L.
    Giugliano, Robert P.
    Wiviott, Stephen D.
    Atar, Dan
    Keech, Anthony
    Kuder, Julia F.
    Im, KyungAh
    Murphy, Sabina A.
    Flores-Arredondo, Jose H.
    Lopez, J. Antonio G.
    Elliott-Davey, Mary
    Wang, Bei
    Monsalvo, Maria Laura
    Abbasi, Siddique
    Sabatine, Marc S.
    CIRCULATION, 2022, 146 (15) : 1109 - 1119
  • [32] Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease
    O'Donoghue, Michelle L.
    Giugliano, Robert P.
    Sabatine, Marc S.
    CIRCULATION, 2023, 147 (16) : 1258 - 1259
  • [33] Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
    Kazi, Dhruv S.
    Moran, Andrew E.
    Coxson, Pamela G.
    Penko, Joanne
    Ollendorf, Daniel A.
    Pearson, Steven D.
    Tice, Jeffrey A.
    Guzman, David
    Bibbins-Domingo, Kirsten
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (07): : 743 - 753
  • [34] Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke
    Ting Zhang
    Yajing Zhang
    Yun Yang
    Haibing Liao
    Xun Li
    Ran Liu
    Xueqing Liu
    Liqin Yang
    Wei Yue
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 302 - 311
  • [35] Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk
    Greving, Jacoba P.
    Buskens, Erik
    Koffijberg, Hendrik
    Algra, Ale
    CIRCULATION, 2008, 117 (22) : 2875 - 2883
  • [36] Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke
    Zhang, Ting
    Zhang, Yajing
    Yang, Yun
    Liao, Haibing
    Li, Xun
    Liu, Ran
    Liu, Xueqing
    Yang, Liqin
    Yue, Wei
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (02) : 302 - 311
  • [37] Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease
    Derdeyn, CP
    Powers, WJ
    STROKE, 1996, 27 (11) : 1944 - 1950
  • [38] Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease
    Ferket, Bart S.
    Hunink, M. G. Myriam
    Khanji, Mohammed
    Agarwal, Isha
    Fleischmann, Kirsten E.
    Petersen, Steffen E.
    HEART, 2017, 103 (07) : 491 - 499
  • [39] COST-EFFECTIVENESS OF EVOLOCUMAB FOR THE TREATMENT OF PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE KINGDOM OF SAUDI ARABIA
    Alghamdi, A.
    Balkhi, B.
    Altowaijri, A.
    Alshehri, N.
    AlHabib, K. F.
    Ralph, L.
    Marriott, E. R.
    Perlaza, Garcia J.
    al-Janad, F.
    Aziziyeh, R.
    VALUE IN HEALTH, 2020, 23 : S95 - S96
  • [40] Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden
    Landmesser, Ulf
    Lindgren, Peter
    Hagstrom, Emil
    Hout, Ben van
    Villa, Guillermo
    Pemberton-Ross, Peter
    Arellano, Jorge
    Svensson, Maria Eriksson
    Sibartie, Mahendra
    Fonarow, Gregg C.
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2022, 8 (01) : 31 - 38
12345